Corporate Profile Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Analyst Coverage Financial Filings SEC Filings Corporate Governance Documents & Charters Management Team Board of Directors Investor Resources Investor FAQs Investor Email Alerts Contact IR Year None2022202120202019 Aug 11, 2022 Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update Jul 06, 2022 Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 Jun 22, 2022 Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma May 18, 2022 Ikena Oncology to Participate in Spring 2022 Investor Conferences May 12, 2022 Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update May 02, 2022 Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration Apr 28, 2022 Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Apr 13, 2022 Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development Mar 17, 2022 Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Mar 07, 2022 Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting Current page 1 Page 2 Next page next › Last page last » Print Page Email Alerts RSS Feeds
Year None2022202120202019 Aug 11, 2022 Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update Jul 06, 2022 Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 Jun 22, 2022 Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma May 18, 2022 Ikena Oncology to Participate in Spring 2022 Investor Conferences May 12, 2022 Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update May 02, 2022 Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration Apr 28, 2022 Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Apr 13, 2022 Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development Mar 17, 2022 Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Mar 07, 2022 Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting Current page 1 Page 2 Next page next › Last page last »
Aug 11, 2022 Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Jun 22, 2022 Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
May 12, 2022 Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 02, 2022 Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration
Apr 28, 2022 Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Apr 13, 2022 Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development
Mar 17, 2022 Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Mar 07, 2022 Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting
